Cosmo Pharmaceuticals saw the highest growth of 99% in patent filings in December and 99% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw no growth in patent filings and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of Cosmo Pharmaceuticals’s patent filings and grants. Buy the databook here.
Cosmo Pharmaceuticals has been focused on protecting inventions in Argentina(AR) with one publication in Q4 2023
The Argentina(AR) Patent Office dominates the patent filings and grants with nearly 25% filings and 0% grants. The Argentina(AR), Australia(AU), Hungary(HU), and Canada(CA) patent Office are among the top ten patent offices where Cosmo Pharmaceuticals is filings its patents. Among the top granted patent authorities, Cosmo Pharmaceuticals has 33% of its grants in Canada(CA) and 33% in Croatia(HR).
Patents related to artificial intelligence and machine learning lead Cosmo Pharmaceuticals's portfolio
Cosmo Pharmaceuticals has the highest number of patents in artificial intelligence followed by, machine learning and healthtech. For artificial intelligence, nearly 43% of patents were filed and 22% of patents were granted in Q4 2023.
Digital signal processors(dsp) related patents lead Cosmo Pharmaceuticals portfolio followed by image management, and active and passive safety
Cosmo Pharmaceuticals has highest number of patents in digital signal processors(dsp) followed by image management, active and passive safety, mos micro (mpu, mcu & dsp), and healthcare it. For digital signal processors(dsp), nearly 33% of patents were filed and 12% of patents were granted in Q4 2023.
For comprehensive analysis of Cosmo Pharmaceuticals's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.